38th week of 2015 patent applcation highlights part 8 |
Patent application number | Title | Published |
20150258032 | Compositions of Antioxidants and Oil for an antioxidant paste or supplement or liquid or frozen product - The invention provides ways to make high antioxidant highly nutritious natural powders appealing and palatable in additives or spreads or drinks or snacks or frozen products or more bio-available in capsules to consumers. | 2015-09-17 |
20150258033 | CONTROLLED RELEASE COMPOSITION AND METHOD - In one aspect, the present invention is directed to a method of making a controlled release solid dosage form having an ethylcellulose coating layer, which layer comprises a coalescing agent which is an organic ester having an HLB Value of from 3 to 8. The use of such coalescing agent permits the formation of an effective controlled release coating without the need for a further curing step after the coating process. In other aspects, this invention relates to an aqueous dispersion useful in such method; as well as to the coated dosage form produced. | 2015-09-17 |
20150258034 | GOLD/LANTHANIDE NANOPARTICLE CONJUGATES AND USES THEREOF - The present disclosure is directed generally to gold/lanthanide nanoparticle conjugates, such as gold/gadolinium nanoparticle conjugates, nanoparticle conjugates including polymers, nanoparticle conjugates conjugated to targeting agents and therapeutic agents, and their use in targeting, treating, and/or imaging disease states in a patient. | 2015-09-17 |
20150258035 | Patches and Methods for the Transdermal Delivery of a Therapeutically Effective Amount of Iron - Embodiments of the invention provide patches for the transdermal delivery of iron-containing compositions to an individual suffering from an iron deficiency. Many embodiments provide an iontophoretic patch for the transdermal delivery of a therapeutically effective amount of iron. The patch comprises an electrode and a reservoir containing a composition comprising ionic iron for the delivery of the therapeutically effective amount of iron. Various embodiments provide methods of using embodiments of the iontophoretic patch for delivering a therapeutically effective amount of iron to an individual suffering from one more forms of iron deficiency including iron deficiency anemia. Such methods can be used for treating and/or preventing the iron deficiency. The amount of delivered iron can be adjusted depending upon various treatment parameters such as patient weight and type and amount of iron deficiency. | 2015-09-17 |
20150258036 | TRANSDERMAL DRUG DELIVERY SYSTEM CONTAINING DONEPEZIL - Certain embodiments of the invention relates to a transdermal drug delivery system containing donepezil or a pharmaceutically acceptable salt thereof as an active ingredient, more specifically to a transdermal drug delivery system containing a drug-containing matrix layer comprising donepezil or its pharmaceutically acceptable salt, a styrene copolymer, a hydrogenated rosin glycerol ester, and optionally a hydrocarbon resin. | 2015-09-17 |
20150258037 | TRANSDERMAL DOSAGE FORM FOR LOW-MELTING POINT ACTIVE AGENT - A drug-containing patch allows transdermal administration of a drug. The patch features a hydrophobic reservoir containing the drug, where the reservoir has a first surface and a second surface. A drug-impermeable backing overlies the first surface of the reservoir. A release sheet may overlie the second surface of the reservoir. The hydrophobic reservoir contains a drug and a hydrophobic matrix, where the hydrophobic matrix includes a hydrophobic filler in an amount which is effective to adsorb said drug; and a mixture of polyisobutylene and mineral oil. The hydrophobic matrix may contain hydrophobic colloidal silica as the hydrophobic filler. The hydrophobic reservoir layer may serve as a skin-contacting adhesive layer. Alternatively, a release-controlling adhesive layer may serve as the skin-contacting adhesive layer. The release-controlling adhesive layer may contain hydrophobic colloidal silica and a mixture of polyisobutylene and mineral oil. | 2015-09-17 |
20150258038 | STABLE AND BIOAVAILABLE COMPOSITIONS OF ISOMERS OF CAROTENOIDS FOR SKIN AND HAIR - The present invention relates to compositions that provide health benefits and methods regarding same are presented. In an embodiment, the present invention provides a primary composition comprising at least one carotenoid-containing material, enriched in Z isomers of the carotenoid compound. For example, the carotenoid-containing material contains by weight a greater percentage of an isomer selected from the group consisting of 5-Z, 9-Z and combinations thereof than of 13-Z isomer. | 2015-09-17 |
20150258039 | PREPARATION OF GGA AND DERIVATIVES THEREOF AND THEIR CO-CRYSTALLIZATION WITH UREA OR THIOUREA - Provided herein are compositions comprising co-crystals of GGA or a GGA derivative (including salts and tauotomers thereof) with urea or thiourea, and processes related to such co-crystals. Also provided herein are methods, compounds, and compositions related to preparing trans GGA and derivatives thereof, and intermediates thereto. | 2015-09-17 |
20150258040 | COMPOSITIONS AND METHODS FOR TREATMENT OF OCULAR INFLAMMATION AND/OR PAIN - The disclosure provides methods of treatment of ocular inflammation and/or neuropathic pain in a subject in need thereof, comprising administering to the subject in need thereof a CB2 target agent, a cannabimimetic agent or a combination thereof. The agent is optionally a cannabinoid, such as a non-psychotropic cannabinoid or a synthetic cannabinoid. In certain embodiments, the non-psychotropic phytocannabinoid is β-caryophyllene or cannabidiol [CBD] and the synthetic cannabinoid is HU-433, HU-308, or a modified CBD such as CBD-DMH. In methods of the disclosure, CBD-DMH is optionally administered in combination with a further CB2 target agent or cannabimimetic agent. The disclosure also provides ocular pharmaceutical compositions containing the CB2 target agents and/or cannabimimetic agents described herein. | 2015-09-17 |
20150258041 | TREATING OSTEOPENIA AND RELATED DISORDERS WITH GERANYLGERANYL ACETONE AND DERIVATIVES THEREOF - Provide herein are methods for treating osteopenia with geranylgeranyl acetone (GGA) and derivatives thereof and compositions useful for the same. | 2015-09-17 |
20150258042 | MODIFIED AND IMMEDIATE RELEASE FORMULATIONS OF MEMANTINE - The present invention provides immediate release and modified release oral dosage forms. Specifically, the invention provides modified and immediate release pharmaceutical dosage forms containing memantine that exhibit an enhanced release profile and provide reliable absorption. The dosage forms may be used to treat mild, moderate or severe Alzheimer's disease or neuropathic pain. | 2015-09-17 |
20150258043 | USE OF SPHINGOID LONG CHAIN BASES AND THEIR ANALOGS IN TREATING AND PREVENTING BACTERIAL INFECTIONS - Methods of preventing or treating bacterial infections, including but not limited to | 2015-09-17 |
20150258044 | METHODS OF TREATMENT USING ARYLCYCLOPROPYLAMINE COMPOUNDS - Described herein are methods of treating Parkinson's disease using arylcyclopropylamine compounds. | 2015-09-17 |
20150258045 | INTRAVENOUS ADMINISTRATION OF TRAMADOL - A method of treating pain, e.g., acute post-operative pain, by administering to a human patient(s) a therapeutically effective dose of tramadol intravenously over a prolonged time period is disclosed. In certain embodiments, the dose is intravenously administered in a time period from about 10 minutes to about 3 hours, preferably from about 10 minutes to about 30 minutes. In other embodiments, intravenous doses are administered at suitable time intervals over a time period from about 3 hours to 48 hours. | 2015-09-17 |
20150258046 | Doxorubicin Adjuvants to Reduce Toxicity and Methods for Using the Same - Methods are provided for using doxorubicin active agents in which reduced host toxicity is observed. Aspects of the methods including administering to a subject an effective amount of a doxorubicin active agent in conjunction with a doxorubicin toxicity-reducing adjuvant, e.g., a nitrone compound, or a nitrone compound in combination with a bisdioxopiperazine compound. Also provided are compositions for use in practicing the subject methods. The methods and compositions find use in a variety of different applications, including in the treatment of a variety of different disease conditions. | 2015-09-17 |
20150258047 | Therapeutic Compounds - The invention relates to compounds which are active as drugs for stimulating the innate antimicrobial peptide system and can be used as antimicrobial drugs. Preferred targets are infections selected from infection of the lung, trachea, urinary tract or kidney, upper GI tract and\or blood. Preferred target pathogens are selected from: | 2015-09-17 |
20150258048 | THERAPEUTIC AGENTS - The invention provides well-defined compounds that are either EP | 2015-09-17 |
20150258049 | X-RAY CONTRAST MEDIA COMPOSITIONS AND METHODS OF USING THE SAME TO TREAT, REDUCE OR DELAY THE ONSET OF CNS INFLAMMATION AND INFLAMMATION ASSOCIATED CONDITIONS - Embodiments disclosed herein relate to improved X-ray contrast media compositions and methods of using the same for treating symptoms related to allergic reactions, inflammatory conditions, symptoms of the common cold and certain cancers. | 2015-09-17 |
20150258050 | METHOD FOR REDUCING TRIGLYCERIDES - The present disclosure relates to docosapentaneoic acid (DPA) of the omega-3 type (DPA 22:5n-3) or derivative thereof and its use in reducing hypertriglyceridemia in a subject in need thereof. In particular, the disclosure relates to the ability of n-3 DPA to significantly decrease the incorporation of fatty acids in chylomicrons in the post-prandial setting. | 2015-09-17 |
20150258051 | METHODS OF INCREASING EPA BLOOD LEVELS - In various embodiments, the present invention provides methods of treating and/or preventing cardiovascular-related disease and, in particular, a method of blood lipid therapy comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof. | 2015-09-17 |
20150258052 | METHODS OF USING FEXARAMINE AND AGENTS THAT INCREASE SYMPATHETIC NERVOUS SYSTEM ACTIVITY TO PROMOTE BROWNING OF WHITE ADIPOSE TISSUE - Provided are methods of promoting browning of white adipose tissue (WAT) in a subject. Such methods can include administering to a subject (e.g., via the gastrointestinal tract) a therapeutically effective amount of fexaramine in combination with a therapeutically effective amount of a compound that mimics or increases sympathetic nervous system activity (e.g., one or more beta-adrenergic agonists and/or compounds that increase epinephrine secretion). | 2015-09-17 |
20150258053 | Methods for Treating Hyperuricemia in Patients with Gout Using Halofenate or Halofenic Acid and a Second Urate-Lowering Agent - Disclosed herein are pharmaceutical compositions, methods and kits for lowering the serum uric acid level of a subject and for the treatment of a condition associated with elevated serum uric acid levels comprising administering a composition comprising a first urate-lowering agent and a second urate-lowering agent. In some aspects the first urate-lowering agent is (−)-halofenate, (−)-halofenic acid, or a pharmaceutically acceptable salts thereof. In some aspects the second urate-lowering agent is an inhibitor of uric acid production, a uricosuric agent, a uricase, or a pharmaceutically acceptable salt thereof. | 2015-09-17 |
20150258054 | COMPOSITIONS AND METHODS FOR TREATING NON-ALCOHOLIC STEATOHEPATITIS - Compositions and method are disclosed comprising ethyl icosapentate for use in treatment of non-alcoholic steatohepatitis (NASH). | 2015-09-17 |
20150258055 | METHODS FOR MODULATING CORTISOL LEVELS USING GREEN COFFEE BEAN EXTRACT - Methods to modulate/reduce cortisol levels in humans are described. Compositions comprising therapeutically effective amount green coffee bean extract, the green coffee extract containing at least 20% chlorogenic acids by dry weight, are administered to human subjects to reduce levels. | 2015-09-17 |
20150258056 | USE OF miR-221 AND 222 LOWERING AGENTS TO PREVENT CARDIOVASCULAR DISEASE IN DIABETIC SUBJECTS - The present invention relates to methodology for preventing increased cardiovascular disease in subjects with diabetes mellitus. The methods include the use of compounds to inhibit activation of the extracellular response kinase pathway, activate 5′ adenosine monophosphate protein kinase, and inhibit microRNA-221 and microRNA-222 for the purpose of reducing microRNA-221 and -222 levels in the vasculature. Reduction of microRNA-221 and -222 in the vasculature of diabetic patients restores normal levels of intimal thickening and enhances the effectiveness of the standard of care in diabetic subjects. | 2015-09-17 |
20150258057 | FATTY ACID DERIVATIVES FOR TREATING INFECTIOUS DISEASES - The present invention relates to a fatty acid metal salt, where said fatty acid comprises 6 to 12 carbon atoms, said salt being a copper salt or a zinc salt, and compositions comprising same, for use in altering the lipid bilayer of cell membranes, and in particular for use as a medicine, as a cosmetic agent, as a medical device, as a food composition, as a nutraceutical or a food supplement. | 2015-09-17 |
20150258058 | Compounds For Enhancing Hypoxia Inducible Factor Activity And Methods Of Use - The present invention relates to methods for enhancing Hypoxia inducible factor-1 (HIF) activity in a cell by contacting the cell with any one of the following compounds: 3,6-bis[2-(dimethylamino)ethoxy]-9h-xanthen-9-onedihydrochloride, 2,8-bis[dimethylaminoacetyl]dibenzofurin dihydrochloride hydrate, tilorone analogue R-9536-DA, indoprofen, ciclopiroxolamine, tryptophan, ansindione, nabumetone, oxybendazole, albendazole, tropicamide, pramoxine hydrochloride, atenolol, mebendazole, carbetapentane citrate, monensin sodium, methoxyvone, hydroxyzine, phenazopyridine, clofoctol, ipraflavone, zomepirac, biochanin A, xylometazoline hydrochloride, fenbendazole, pirenzepine, triprolidine hydrochloride, daidzein, tripelennamine citrate, colchicines, aminopyridine, trimethoprim, helenine, hydroxyurea, amiodarone hydrochloride, clindamycin hydrochloride, sulfachlorpyridazine, mephenesin, semustine, clofivric acid, clofibrate, ibuprofen, hyoscyamime, nafcillin sodium, piperin, clidinium bromide, trioxsalen, hydralazine and HIF alpha protein fused to a carrier peptide. | 2015-09-17 |
20150258059 | ANTIMICROBIAL AND RADIOPROTECTIVE COMPOUNDS - The present invention relates to a method of treatment and/or prophylaxis of a microbial infection, comprising the step of administering an effective amount of a compound of formula (I), in which X and Y are either the same or different and selected from a heteroatom; is a double or single bond depending on the heteroatoms X and Y; R | 2015-09-17 |
20150258060 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER - Exemplary embodiments relate to a novel anticancer composition including a compound represented by chemical formula 1 or pharmaceutically acceptable salt thereof as an active ingredient: | 2015-09-17 |
20150258061 | COMPOSITIONS AND METHODS FOR TREATMENT OF NEURODEGENERATIVE DISEASE - Compounds, compositions, kits and methods for treating conditions related to neurodegeneration or ocular disease, are disclosed. | 2015-09-17 |
20150258062 | COMPOSITIONS AND METHODS FOR TREATMENT OF RENAL DISEASE - The invention relates to methods, compositions, and kits for the treatment of proteinuria and/or hypertension (e.g., proteinuria and/or hypertension arising from primary renal disease (e.g., focal segmental glomerulosclerosis, glomerular disease) or secondary to other conditions (e.g., diabetes, diabetic nephropathy, liver disease). Specifically, the invention relates to methods involving combination therapy wherein an indoline (e.g., indapamide) is administered in combination with an anti-aldosterone agent (e.g., spironolactone and/or epleronone). | 2015-09-17 |
20150258063 | ISOTOPOLOGUES OF ISOINDOLE DERIVATIVES - Provided herein are isoindole derivatives, which is enriched with isotopes such as deuterium. Pharmaceutical compositions comprising the isotopes-enriched compounds, and methods of using such compounds are also provided. | 2015-09-17 |
20150258064 | MELATONIN-BASED FORMULATIONS FOR PARENTERAL ADMINISTRATION - Pharmaceutical formulations comprising nanoparticles of melatonin are useful for the treatment of neonatal brain injury. | 2015-09-17 |
20150258065 | METHODS AND COMPOSITIONS FOR TRANSDERMAL DELIVERY - One aspect of the invention relates to AI-helper compositions comprising an AI compound (e.g., melatonin) and one or more helper esters. The AI-helper compositions disclosed herein can be used for effective transdermal delivery of the AI compound to a subject. Another aspect of the invention relates to applications and preparations of the AI-helper compositions. | 2015-09-17 |
20150258066 | METHOD FOR PRODUCING FINE POWDER AND THE FINE POWDER PRODUCED BY THE SAME - Disclosed is a method for producing a fine powder. Two or more kinds of original materials are suspended and liquefied inert gas to form two or more kinds of slurries wherein each slurry contains at least one or more different kinds of original materials. Granular dry ice grinding medium is put into the slurries. The slurries are individually stirred and the original materials are pulverized into submicron-sized or nano-sized particles in the liquefied inert gas. The slurries are thereafter mixed. The liquefied inert gas is vaporized and the granular dry ice is sublimated. A mixture of the particles of the two or more kinds of original materials is recovered. | 2015-09-17 |
20150258067 | VETERINARY METHOD OF ALLEVIATING NOISE AVERSION - The invention relates to a method for alleviating noise aversion in animals, particularly dogs, comprising administering to a subject in need thereof an effective amount of dexmedetomidine, medetomidine or a pharmaceutically acceptable salt thereof as the active ingredient. The active ingredient is preferably administered oromucosally, e.g. in the form of an oromucosal gel. | 2015-09-17 |
20150258068 | COMBINATION THERAPIES - Provided herein are methods of treating a disease or disorder associated with dysregulation of histone deacetylase, and more specifically sensitizing and treating chemoresistant cancer comprising administering a therapeutically effective amount of a combination comprising a benzimidazole compound and a DNA hypomethylating agent and kits containing said combination. The preferred DNA hypomethylating agent used in the method is 5-azacitidine azacitidine. | 2015-09-17 |
20150258069 | Bendamustine Solid Dispersions And Continuous Infusion - Provided herein are pharmaceutical compositions comprising nitrogen mustard, for example bendamustine hydrochloride, solid dispersions substantially free of degradants. Also provided are methods of producing and administering nitrogen mustards and in particular bendamustine hydrochloride solid dispersions substantially free of degradants. The pharmaceutical compositions can be used for any disease that is sensitive to treatment with bendamustine hydrochloride, such as neoplastic diseases. | 2015-09-17 |
20150258070 | Oral Dosage Forms of Bendamustine and Therapeutic Use Thereof - In the present invention there is provided a pharmaceutical composition for oral administration which comprises bendamustine or a pharmaceutically acceptable, ester, salt or solvate thereof as an active ingredient, and a pharmaceutically acceptable excipient and which shows a dissolution of the bendamustine of at least 60% in 20 minutes, 70% in 40 minutes and 80% in 60 minutes, as measured with a paddle apparatus at 50 rpm according to the European Pharmacopoeia in 500 ml of a dissolution medium at a pH of 1.5. The invention further relates to the above pharmaceutical composition for use for the oral treatment of a medical condition which is selected from chronic lymphocytic leukemia, acute lymphocytic leukaemia, chronic myelocytic leukaemia, acute myelocytic leukaemia, Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, breast cancer, ovarian cancer, small cell lung cancer and non-small cell lung cancer. | 2015-09-17 |
20150258071 | Method for Topically Treating Actinic Keratosis on the Trunk (except chest) Or Extremities with ingenol 3-(3,5-diethylisoxazole-4-carboxylate) - The invention relates to the treatment of actinic keratosis on the trunk (except chest) or Extremities with ingenol 3-(3,5-diethylisoxazole-4-carboxylate). | 2015-09-17 |
20150258072 | Antibacterial compositions - A pharmaceutical composition useful for the treatment or control of bacterial infections is disclosed. | 2015-09-17 |
20150258073 | INDICATION OF ANTHRA[2,1,c][1,2,5]THIADIAZOLE-6,11-DIONE COMPOUND IN ALLEVIATING PAIN - Disclosed are anthra[2,1-c][1,2,5]thiadiazole-6,11-dione compounds and pharmaceutical composition thereof. The compounds of the invention have been demonstrated as having analgesic effects and therefore may be applicable for use as a novel agent in relieving acute or chronic pain. | 2015-09-17 |
20150258074 | NOVEL COMPOUNDS THAT ARE ERK INHIBITORS - Disclosed are the ERK inhibitors of formula (1.0), having a pyrazolopyridine base structure, and the pharmaceutically acceptable salts thereof. Also disclosed are methods of treating cancer using the compounds of formula (1.0). | 2015-09-17 |
20150258075 | PYRIDO[4,3-B]INDOLE AND PYRIDO[3,4-B]INDOLE DERIVATIVES AND METHODS OF USE - This disclosure is directed to pyrido[4,3-b]indole and pyrido[3,4-b]indole derivatives. Pharmaceutical compositions comprising the compounds are also provided, as are methods of using the compounds in a variety of therapeutic applications, including the treatment of a cognitive disorder, psychotic disorder, neurotransmitter-mediated disorder and/or a neuronal disorder. The compounds may bind to and antagonize receptor α2B, α1B or α2A. The compounds may find use in therapy, e.g., to (i) reduce blood pressure and/or (ii) promote renal blood flow and/or (iii) decrease or inhibit sodium reabsorption, or to regulate blood glucose level, increase insulin secretion and treat diseases or conditions that are, or are expected to be, responsive to an increase in insulin production. The compounds may also be used to treat diseases or conditions that are expected to be responsive to a decrease in blood pressure. Use of the compounds to treat cardiovascular, renal disorders or type 2 diabetes is particularly described. | 2015-09-17 |
20150258076 | SUBSTITUTED PYRAZOLO[1,5-A] PYRIDINE AS TROPOMYOSIN RECEPTOR KINASE (TRK) INHIBITORS - The present application relates to a series of substituted pyrazolo[1,5-a]pyridine compounds, their use as tropomyosin receptor kinase (Trk) family protein kinase inhibitors, method of making and pharmaceutical compositions comprising such compounds. | 2015-09-17 |
20150258077 | SUBSTITUTED BENZTROPINE ANALOGS FOR TREATMENT OF DEMENTIA - A method for treating a condition selected from Alzheimer's disease, mild cognitive impairment, age-associated dementia, and frontotemporal dementia, comprises administering to a patient in need of such treatment a safe and effective amount of a compound having the formula: | 2015-09-17 |
20150258078 | COMPOSITIONS CONTAINING BERBERINE AND PANTETHINE AND METHODS FOR TREATMENT OF LIPID METABOLISM DISORDERS - The present invention is directed to compositions incorporating purified herbal ingredients for the treatment of conditions such as hypercholesterolemia, hyperlipidemia, elevated triglycerides, syndrome X (metabolic syndrome), hyperglycemia, diabetes, cardiovascular disease and the like as well as disorders of lipid metabolism with failed response to standard therapies (for example statins) or any other disease or condition associated with lipids and lipid metabolism, as well as methods for their use. The compositions incorporating purified herbal ingredients can incorporate combinations of berberine and pantethine, alone or with one or more of chromium polynicotinate or chromium picolinate, biotin, curcumin and/or bioperin. | 2015-09-17 |
20150258079 | COSMETIC OR DERMATOLOGICAL PREPARATION FOR PROPHYLAXIS AND/OR TREATMENT OF ATOPIC DERMATITIS - Agonists for the TRPM-8 receptor, more particularly one or more substances selected from the group of, for example, linalool, geraniol, hydroxycitronellal, WS-3 (N-ethyl-p-menthane-3-carboxamide), WS-23 (2-isopropyl-N,2,3-trimethylbutyramide), Frescolat MAG (1,4-dioxaspiro[4.5]decane-2-methanol), Frescolat ML (menthyl lactate), Coolact P (5-methyl-2-prop-1-en-2-ylcyclohexan-1-ol) and Cooling Agent 10 (menthoxypropanediol), for use as medicaments to counter atopic dermatitis. | 2015-09-17 |
20150258080 | THERAPEUTIC COMBINATIONS WITH ESTROGEN RECEPTOR MODULATORS - Described herein are therapeutic combinations with estrogen receptor modulators for treating diseases or conditions that are mediated or dependent upon estrogen receptors. | 2015-09-17 |
20150258081 | COMBINATION OF A COMPOUND HAVING THE ABILITY TO REARRANGE A LYSOSOMAL ENZYME AND AMBROXOL AND/OR A DERIVATIVE OF AMBROXOL - It is herewith declared that the information stored on the carrier which is submitted together with the international patent application is identical to the written sequence listing of the international patent application. | 2015-09-17 |
20150258082 | COMBINATION THERAPY WITH GLUTAMINASE INHIBITORS - The invention relates to methods of treating cancer, myeloproliferative disorders or immunological diseases with a combination of an immunomodulatory agent and a glutaminase inhibitor. The invention further relates to methods of treating cancer, myeloproliferative disorders, or immunological diseases that are resistant to one or more immunomodulatory agents. | 2015-09-17 |
20150258083 | METHODS FOR THE ADMINISTRATION OF ILOPERIDONE - The present invention relates to methods for the identification of genetic polymorphisms that may be associated with a risk for QT prolongation after treatment with iloperidone and related methods of administering iloperidone to patients with such polymorphisms. | 2015-09-17 |
20150258084 | STEM CELL COMPOSITIONS AND METHODS OF THEIR USE - The present invention relates to admixtures of stem cells and TGF-β inhibitors. The invention provides methods for characterizing, isolating, and culturing stem cells from human tissue samples. The invention also provides compositions and methods useful for treating subjects with disease (e.g. heart disease). | 2015-09-17 |
20150258085 | Treating Tumors of the Central Nervous System - A synergistic therapeutic effect is obtained in CNS cancer patients treated concomitantly with a first antineoplastic agent and a second antineoplastic agent, wherein one or both antineoplastic agents are administered by convection enhanced delivery. Combinations of interest include, without limitation, CED delivery of a topoisomerase inhibitor, e.g., topotecan, and systemic delivery of a triazene, e.g. temozolomide. | 2015-09-17 |
20150258086 | Oxycodone Compositions - In certain embodiments the invention is directed to a process for preparing an oxycodone hydrochloride composition having less than 25 ppm of 14-hydroxycodeinone. | 2015-09-17 |
20150258089 | CONTROLLED RELEASE HYDROCODONE FORMULATIONS - A solid oral controlled-release dosage form of hydrocodone is disclosed, the dosage form comprising an analgesically effective amount of hydrocodone or a pharmaceutically acceptable salt thereof, and controlled release material. | 2015-09-17 |
20150258090 | CONTROLLED RELEASE HYDROCODONE FORMULATIONS - A solid oral controlled-release dosage form of hydrocodone is disclosed, the dosage form comprising an analgesically effective amount of hydrocodone or a pharmaceutically acceptable salt thereof, and controlled release material. | 2015-09-17 |
20150258091 | CYCLIC GLYCYL-2-ALLYL PROLINE IMPROVES COGNITIVE PERFORMANCE IN IMPAIRED ANIMALS - Embodiments of this invention provide methods for therapeutic use of cyclic G-2-Allyl Proline to treat symptoms of cognitive impairment associated with developmental disorders as well as manufacture of medicaments including tablets, capsules, injectable solutions that are useful for treatment of such conditions. | 2015-09-17 |
20150258092 | RIBOSOME STRUCTURE AND PROTEIN SYNTHESIS INHIBITORS - The invention provides methods for producing high resolution crystals of ribosomes and ribosomal subunits as well as crystals produced by such methods. The invention also provides high resolution structures of ribosomal subunits either alone or in combination with protein synthesis inhibitors. The invention provides methods for identifying ribosome-related ligands and methods for designing ligands with specific ribosome-binding properties as well as ligands that may act as protein synthesis inhibitors. Thus, the methods and compositions of the invention may be used to produce ligands that are designed to specifically kill or inhibit the growth of any target organism. | 2015-09-17 |
20150258093 | SOLID ANTIVIRAL DOSAGE FORMS - The present disclosure relates to solid dosage forms comprising antiviral compounds and methods of using such dosage forms to treat antiviral infection. | 2015-09-17 |
20150258094 | Nanocarriers And Their Processing For Diagnostics And Therapeutics - The compositions and methods of the invention provide compositions and methods for preferential targeting of tissues to delivery therapeutic or diagnostic agents. For example, such compounds are useful in the treatment of joint disorders those affecting articulating joints, e.g., injury-induced osteoarthritis as well as autoimmune diseases affecting joint tissue such as rheumatoid arthritis. | 2015-09-17 |
20150258095 | MODULATORS OF ANDROGEN SYNTHESIS - The present specification discloses compositions comprising at least one therapeutic compound capable of modulating androgen production and methods and uses for treating a disorder associated with androgen production using such compositions and/or compounds. | 2015-09-17 |
20150258096 | METHODS AND COMPOSITIONS FOR TREATMENT OF TH2-MEDIATED AND TH17-MEDIATED DISEASES - Provided herein, inter alia, are methods drawn to treatment of Th2-mediated and Th17-mediated diseases. Also provided herein is a mouse model that develops Th2 responses to environmental stimuli in a similar manner as human subjects. | 2015-09-17 |
20150258097 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CATATONIA - Compositions and methods for treating psychotic and neurological disorders in a subject are disclosed. The compositions and methods utilize a pharmaceutical compound that reverses or negates the effects of an NMDA receptor antagonist. The compositions and methods are effective in reducing at least catatonic features in the subject. | 2015-09-17 |
20150258098 | PHARMACEUTICAL COMPOSITION OF 1-ADAMANTYLETHYLOXY-3-MORPHOLINO-2-PROPANOL OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF FOR THE TREATMENT OF CEREBROVASCULAR DISEASE AND NEURODEGENERATIVE DISEASES OF THE CENTRAL NERVOUS SYSTEM - A pharmaceutical composition for parenteral administration containing the active ingredient 1-adamantylethyloxy-3-morpholino-2-propanol, or pharmaceutically acceptable salts thereof, in a concentration range of from 3 to 100 mg/ml for the treatment of cerebrovascular disease. | 2015-09-17 |
20150258099 | METHODS AND COMPOSITIONS FOR MODULATING ESTROGEN RECEPTOR MUTANTS - Described herein are methods and compositions for treating an ER-related disease condition characterized by a mutation in the ESR1 gene by administering an estrogen receptor modulator. Also described herein are methods of treating hormone resistant-estrogen receptor (ER) positive breast cancers characterized by a mutation in the ESR1 gene by administering an estrogen receptor modulator. | 2015-09-17 |
20150258100 | ANTIBACTERIAL PROTEIN KINASE INHIBITORS - Methods of treating bacterial infection by in a subject by administering a pharmaceutical composition including a celecoxib derivative are described. The compounds are particularly useful for treating infection by bacteria capable of growing inside macrophages, such as | 2015-09-17 |
20150258101 | NEW COMPOUNDS - The present invention provides certain compounds according to formula (I) which are inhibitors of SSAO activity | 2015-09-17 |
20150258102 | THERAPEUTIC NANOPARTICLES COMPRISING A THERAPEUTIC AGENT AND METHODS OF MAKING AND USING SAME - The present disclosure generally relates to nanoparticles comprising a substantially hydrophobic acid and a therapeutic agent (1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea), or pharmaceutically acceptable salts thereof, and a polymer. Other aspects include methods of making and using such nanoparticles. | 2015-09-17 |
20150258103 | USE OF RESAZURIN, OR ANALOGS THEREOF, FOR ANTIBACTERIAL THERAPY - A method for treating infection by bacteria in a subject, comprising administering to the subject a therapeutically effective amount of resazurin or a resazurin analog, or a pharmaceutically acceptable salt or ester thereof, wherein the bacteria is selected from at least one of | 2015-09-17 |
20150258104 | USE OF NORIBOGAINE FOR THE TREATMENT OF PAIN - This invention is directed to methods of treating pain in patients comprising treating patients with noribogaine at a dosage that provides an average serum concentration of 50 ng/mL to 180 ng/mL, including under conditions where the QT interval prolongation does not exceed about 50 milliseconds. | 2015-09-17 |
20150258105 | METHODS FOR ACUTE AND LONG-TERM TREATMENT OF ALCOHOL DEPENDENCE - This invention is directed to a method of treating alcohol dependence, including acute and post-acute withdrawal symptoms, comprising treating an alcohol dependent patient with noribogaine, noribogaine derivative, or pharmaceutically acceptable salt and/or solvate thereof at a dosage that provides an average serum concentration of about 50 ng/mL to about 850 ng/mL under conditions where the QT interval prolongation does not exceed about 50 milliseconds. | 2015-09-17 |
20150258106 | METHODS FOR ACUTE AND LONG-TERM TREATMENT OF SUBSTANCE ABUSE - This invention is directed to a method of treating drug addiction, including acute and post-acute withdrawal symptoms, comprising treating an addicted patient with noribogaine or a pharmaceutically acceptable salt and/or solvate thereof at a dosage that provides a therapeutic serum concentration. In one embodiment, the average serum concentration is 50 ng/mL to 180 ng/mL under conditions where the QT interval prolongation does not exceed about 50 milliseconds, and preferably about 30 milliseconds. | 2015-09-17 |
20150258107 | METHODS AND COMPOSITIONS FOR TREATING DEPRESSION - This invention provides a method for treating depression and/or posttraumatic stress disorder in a patient, comprising administering to the patient in need thereof a therapeutically effective amount of noribogaine, noribogaine derivative, or a pharmaceutically acceptable salt and/or solvate thereof. | 2015-09-17 |
20150258109 | LOW DOSE ADMINISTRATION OF IBOGAINE FOR TREATING NICOTINE ADDICTION AND PREVENTING RELAPSE OF NICOTINE USE - This invention relates generally to methods and compositions for the treatment of nicotine addiction by administering ibogaine, an ibogaine derivative, or a pharmaceutically acceptable salt and/or solvate thereof to a patient in low doses. This invention further relates generally to methods and compositions for the treatment or prevention of relapse of nicotine use by administering ibogaine, an ibogaine derivative, or a pharmaceutically acceptable salt and/or solvate thereof to a patient in low doses. | 2015-09-17 |
20150258110 | METHODS FOR ACUTE AND LONG-TERM TREATMENT OF ALCOHOL DEPENDENCE USING IBOGAINE - This invention is directed to a method of treating alcohol dependence, including acute and post-acute withdrawal symptoms, comprising treating an alcohol dependent patient with ibogaine, ibogaine derivative, or pharmaceutically acceptable salt and/or solvate thereof at a dosage that provides an average serum concentration of about 50 ng/mL to about 850 ng/mL under conditions where the QT interval prolongation does not exceed about 50 milliseconds. | 2015-09-17 |
20150258112 | METHODS AND COMPOSITIONS FOR TREATING DEPRESSION USING IBOGAINE - This invention provides a method for treating depression and/or post-traumatic stress disorder in a patient, comprising administering to the patient in need thereof a therapeutically effective amount of ibogaine, ibogaine derivative, or a pharmaceutically acceptable salt and/or solvate thereof. | 2015-09-17 |
20150258113 | USE OF IBOGAINE FOR THE TREATMENT OF PAIN - This invention is directed to methods of treating pain in patients comprising treating patients with ibogaine, an ibogaine derivative, or a pharmaceutically acceptable salt and/or solvate thereof at a therapeutic dosage that provides an average serum concentration of about 50 ng/mL to about 850 ng/mL. | 2015-09-17 |
20150258114 | METHODS FOR ACUTE AND LONG-TERM TREATMENT OF SUBSTANCE ABUSE USING IBOGAINE - This invention is directed to a method of treating substance addiction, including acute and post-acute withdrawal symptoms, comprising treating an addicted patient with ibogaine, ibogaine derivative, or a pharmaceutically acceptable salt and/or solvate thereof at a dosage that provides an average serum concentration of about 50 ng/mL to about 850 ng/mL under conditions where the QT interval prolongation does not exceed about 50 milliseconds. | 2015-09-17 |
20150258115 | PHARMACEUTICAL COMPOSITIONS COMPRISING SORBITAN ESTERS - The present invention relates to a pharmaceutical composition comprising sorbitan esters of carboxylic acids that are useful for the delivery of anti-psychotic drugs. | 2015-09-17 |
20150258116 | Synergistic Microbicidal Combinations - Antimicrobial compositions based on the synergistic combination of 2-methyl-3-isothiazolone and selected commercial microbicides where the compositions are substantially free of halogenated 3-isothiazolone, are disclosed. Particularly preferred are combinations of 2-methyl-3-isothiazolone together with benzoic acid, citric acid, sorbic acid, 1,2-dibromo-2,4-dicyanobutane, 1,3-dimethylol-5,5-dimethylhydantoin, phenoxyethanol, benzyl alcohol, zinc pyrithione or climbazole, that provide enhanced microbicidal efficacy at a combined active ingredient level lower than that of the combined individual 3-isothiazolone and commercial microbicide effective use levels. | 2015-09-17 |
20150258117 | LOW-DOSE ESTRADIOL CREAM - A low-dose estradiol cream for vaginal administration that is safe and clinically effective to treat symptoms of menopause and a kit comprising the low-dose estradiol cream and an applicator are provided. A method of treatment of the symptoms of vulvar and/or vaginal atrophy associated with menopause, that includes the step of vaginally administering the low-dose estradiol cream to a woman in need thereof is also provided. | 2015-09-17 |
20150258118 | CO-MICRONISATION PRODUCT COMPRISING A SELECTIVE PROGESTERONE-RECEPTOR MODULATOR - The subject of the present invention is a co-micronization product comprising: an active ingredient selected from the group consisting of selective progesterone receptor modulators, metabolites thereof and mixtures thereof, and an N-vinyl-2-pyrrolidone-based polymeric excipient. The invention also relates to a pharmaceutical composition comprising said co-micronization product and to the therapeutic uses thereof. | 2015-09-17 |
20150258119 | TOPICAL CORTICOSTEROID COMPOSITIONS - Compositions for the topical administration of an active agent comprising a corticosteroid and a fatty alcohol as skin penetration enhancer, in the form of topical sprays. Processes for preparing such compositions and methods of using them in management of skin diseases or disorders such as psoriasis, dermatoses, and other associated skin diseases or disorders. | 2015-09-17 |
20150258120 | METHODS AND DEVICES FOR THE TREATMENT OF OCULAR DISEASES IN HUMAN SUBJECTS - Methods and devices are provided for targeted non-surgical administration of a drug formulation to the suprachoroidal space (SCS) of the eye of a human subject for the treatment of a posterior ocular disorder or a choroidal malady. In one embodiment, the method comprises inserting a hollow microneedle into the eye at an insertion site and infusing a drug formulation through the inserted microneedle and into the suprachoroidal space of the eye, wherein the infused drug formulation flows within the suprachoroidal space away from the insertion site during the infusion. In one embodiment, the fluid drug formulation comprises drug nanoparticles or microparticles. | 2015-09-17 |
20150258121 | COMPOSITIONS AND METHODS FOR FORMING STABILIZED COMPOSITIONS WITH REDUCED CSA AGGLOMERATION - Compositions and methods for preparing stabilized CSA compositions having reduced agglomeration and increased stability. The compositions have increased efficacy in killing microbes and reduced cytotoxicity to mammals. The compositions include a liquid carrier, micelles formed from an amphiphilic material, and CSA molecules encapsulated by the micelles. The CSA compositions can be formed by blending together a solvent or liquid carrier, a plurality of CSA molecules, and a micelle-forming agent and causing or allowing the micelle-forming agent to form micelles encapsulating at least a portion of the CSA molecules so that no more than 25% of the CSA molecules form agglomerates larger than 1 μm in size. The CSA compositions can be used to treat mammals, such as mammals suffering from microbial diseases or infections. | 2015-09-17 |
20150258122 | LAVAGE AND/OR INFUSION USING CSA COMPOUNDS FOR INCREASING FERTILITY IN A MAMMAL - Increasing fertility in a mammal utilizes cationic steroidal antimicrobial (CSA) compounds and CSA-containing compositions. Such treatment in a mammal includes administering a formulation (e.g., lavage and/or infusion) including at least one CSA compound, or pharmaceutically acceptable salt thereof, to the reproductive structure(s) of the mammal (e.g., horse, dairy cow, human, etc.). The formulation may be applied topically as lavage and/or infusion to desired reproductive structures, such as the vagina, cervix, uterus, penis, or combinations thereof. The formulation may kill both planktonic and biofilm forms of sperm killing microbes, and may at least partially break up a microbial plaque or film located within any of the reproductive structures (e.g., the uterus). The CSA or pharmaceutically acceptable salt thereof may be selective or preferential in its action, so as to preferentially kill sperm killing microbes without causing harm to beneficial microbes also residing within the reproductive structure of the mammal. | 2015-09-17 |
20150258123 | ANTI-INFECTIVE AND OSTEOGENIC COMPOSITIONS AND METHODS OF USE - Cationic steroidal antimicrobials (“CSAs” or “ceragenins”) and methods of making and using the same. Particularly advantageous uses include treating infections in patient and sub-patient populations, especially those having a bone disease, a broken bone, a bone infection, or a bone implant. | 2015-09-17 |
20150258124 | COMPOSITIONS AND METHODS FOR PROMOTING INTESTINAL STEM CELL FUNCTION - Disclosed herein are novel methods and compositions useful for promoting intestinal stem cell function. The methods and compositions are particularly useful for stimulating the proliferation of and/or self-renewal of intestinal stem cells, as well as for minimizing, preventing, or ameliorating cellular damage resulting from incidental or accidental exposure to radiation (e.g., cancer radiation therapy). | 2015-09-17 |
20150258125 | TREATMENT OF CANCER USING HYPOXIA ACTIVATED PRODRUGS - Cancer can be treated by administration of a hypoxia-activated prodrug, such as TH-302, alone or in combination with other anticancer agents and/or radiation therapy. In combination therapy, the hypoxia-activated prodrug and another anticancer agent or radiation therapy may be administered within the same 24-hour period, and administration of the hypoxia-activated prodrug may be completed prior to beginning administration of the other anticancer agent or radiation therapy. | 2015-09-17 |
20150258126 | COMPOSITIONS AND METHODS FOR TREATING BACTERIAL INFECTIONS USING CEFTAROLINE - The present invention relates to compositions comprising ceftaroline or a prodrug thereof (e.g., ceftaroline fosamil) and methods for treating bacterial infections, such as complicated skin and structure infections (cSSSI) and community-acquired bacterial pneumonia (CABP) by administering ceftaroline or a prodrug thereof, (e.g., ceftaroline fosamil). | 2015-09-17 |
20150258127 | METHODS FOR PREVENTING ANTIPHOSPHOLIPID SYNDROME (APS) - The present invention relates to the prevention or treatment of antiphospholipid syndrome (APS) in a patient in need thereof (e.g. patients affected with primary APS, a secondary APS, a catastrophic APS (CAPS) or a transplant recipient with antiphospholipid antibodies (APA)). The present invention also relates to the prevention APS-related vascular lesions in said a patient in need thereof. The present invention further relates to PI3K-AKT-mTOR pathway inhibitor for use in inhibiting endothelial m TORC activation triggered by APA in a patient in need thereof. | 2015-09-17 |
20150258128 | GABAERGIC RECEPTOR SUBTYPE SELECTIVE LIGANDS AND THEIR USES - Described herein are α3 or α2 or α2/α3 GABAergic receptor subtype selective ligands, pharmaceutical compositions, and methods of use of such ligands and compositions in treatment of anxiety disorders, epilepsy and schizophrenia with reduced sedative and ataxic side effects. In embodiments, such as α3 or α2 or α2/α3 GABAergic receptor subtype selective ligands lack ester linkages and may be thus relatively insensitive to hydrolysis by esterases. | 2015-09-17 |
20150258129 | Method for Increasing the Activity of Lysosomal Enzymes - Method for enhancing in a mammalian cell the activity of an enzyme associated with Gaucher Disease by administering a competitive inhibitor of glucocerebrosidase in an amount effective to enhance the activity of the enzyme. Preferred compounds for use in the method are imino sugars and related compounds. In particular, C8-12-alkyl derivatives of N-alkyl-deoxymojirimycin, isofagomine compounds, and calystegine compounds are effective to enhance glucocerebrosidase activity. | 2015-09-17 |
20150258130 | NICKED OR GAPPED NUCLEIC ACID MOLECULES AND USES THEREOF - The present disclosure provides meroduplex (nicked or gapped) ribonucleic acid molecules (mdRNA) that decreases or silences target gene expression. An mdRNA of this disclosure comprises at least three strands that combine to form at least two non-overlapping double-stranded regions separated by a nick or gap wherein one strand is complementary to a target gene RNA. In addition, the meroduplex may have one or more modifications or substitutions, such as nucleotide base, sugar, terminal cap structure, internucleotide linkage, or any combination of such modifications. Also provided are methods of decreasing expression of a target gene in a cell or in a subject to treat a disease related to altered expression of a target gene. | 2015-09-17 |
20150258131 | Peyer's Patch Activator - The present invention provides a Peyer's patch activator containing a polysaccharide obtained from sugar cane as an active ingredient, wherein the polysaccharide contains α-glucan as a main component and has a peak molecular weight within a range of 720,000 to 1,080,000, with a proportion of glucose in all component sugars being 80% or more, and proportions of nonreducing terminal glucose and α-1,6-linked glucose being 20 to 30% and 15 to 25%, respectively. | 2015-09-17 |
20150258132 | RAPID FORMATION OF CHITOSAN SPONGES USING GUANOSINE 5'-DIPHOSPHATE: INJECTABLE SCAFFOLDS FOR TISSUE REGENERATION AND DRUG DELIVERY - It is disclosed Guanosine 5′-Diphosphate (GDP) crosslinked chitosan sponge or gelling composition which is used as a scaffold for tissue regeneration applications such as neural, cardiac, cartilage and bone regeneration. In addition, the sponge acts as a drug delivery system to provide local controlled drug release, such as delivering anti-cancer drugs locally at the tumor site. | 2015-09-17 |
20150258133 | USE OF CYCLODEXTRIN FOR TREATMENT AND PREVENTION OF BRONCHIAL INFLAMMATORY DISEASES - The invention provides the use of a cyclodextrin compound for the manufacturing of a medicament for the treatment or prevention of bronchial inflammatory diseases, particularly for asthma and chronic obstructive pulmonary disease (COPD). | 2015-09-17 |
20150258134 | CHONDROITIN FOR USE IN MEDICINE - Chondroitin, a metabolic intermediate of chondroitin sulphate biosynthesis in mammals and other living organisms, possesses biological properties different from those of chondroitin sulphate, and can be advantageously used for applications in the pharmaceutical, nutraceutical, cosmeceutical and medical device fields. Chondroitin has biostimulating, anti-inflammatory and anti-microbial activity and can be used in the treatment of osteoarthritis, eye disorders, interstitial cystitis, lung disorders, inflammatory disorders in general, oncological disorders, peritoneal dialysis, tissue biorevitalisation and wound repair, as a skin filler, and as bioresorbable scaffolds. | 2015-09-17 |
20150258135 | INJECTABLE ALLOPLASTIC IMPLANTS AND METHODS OF USE THEREOF - Described herein are injectable alloplastic implant compositions that are particularly useful for soft tissue defect augmentation. The compositions include microparticles, such as polymethylmethacrylate particles, and collagen as a suspending agent, wherein the collagen contains a reduced amount of low molecular weight gelatine compared to high molecular weight collagen. By controlling the molecular weight of the collagen in the compositions, the injectability, stability, and antigenicity of the alloplastic implant compositions can be improved. | 2015-09-17 |